Read Summary

Patiehts with stage IV non–small cell lung cancer have better outcomes when tremelimumab is added to durvalumab and chemo, a phase 3 trial shows, but questions remain over the role of anti-CTLA-4 agents.
Medscape Medical News

Print Friendly, PDF & Email